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Abstract 
The bone marrow of low risk myelodysplastic syndromes is often associated with an inflammatory 
environment and active cellular immune response. An active immune response generally contributes 
to anti-tumor responses and may prevent disease progression. However, chronic immune stimulation 
can also induce cell stress, DNA damage and contribute in the pathogenesis of myelodysplastic 
syndromes. Characterizing the protective mechanisms against excessive immune activation is 
therefore an important aspect of the pathophysiology and may help us to better understand the fine 
balance between protective and destabilizing inflammation in lower risk disease. In this study we have 
investigated the role of thrombomodulin (CD141/BDCA-3) expression, a molecule with anti-
inflammatory properties, on monocytes in the bone marrow and peripheral blood of myelodysplastic 
syndrome patients within different risk group. Patient-derived classical monocytes show high 
expression levels of thrombomodulin, whereas monocytes from healthy donors hardly expressed any 
thrombomodulin. The presence of thrombomodulin on monocytes from myelodysplastic syndrome 
patients correlated with lower risk disease groups and a better overall and leukemia-free survival. 
Using multidimensional mass cytometry (CyTOF), in an in-vitro setting, we show that thrombomodulin 
positive monocytes could polarize naïve T cells toward cell clusters which are closer to Th2 and Treg 
phenotypes and less likely to contribute in an effective immune-surveillance. In conclusion, the 
expression of thrombomodulin on classical monocytes is a favorable and early prognostic marker in 
patients with low risk myelodysplastic syndromes and may represent a new mechanism in the 
protection against disproportionate immune activation.   
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Introduction 
The immune system plays an important role in the pathogenesis and disease course of 
myelodysplastic syndromes (MDS). Between several prognostic MDS risk groups, the immune status 
can be markedly different. Low risk disease is often characterized by an increased number and 
activation state of pro-inflammatory immune cells (i.e. T helper (Th)17, natural killer (NK)-cells and 
CD8+ cytotoxic T cells,1–6) whereas in high risk disease an immunosuppressive response is the 
dominant feature (i.e. expansion of T regulatory cells (Tregs,7–10) and myeloid-derived suppressor cells 
11
 which could facilitate immune escape and eventually progression to acute myeloid leukemia (AML). 
Although an “activated” immune system and associated tumor specific immune responses are crucial 
for an effective immune surveillance and elimination of the malignant clone, in longer term however, 
chronic immune stimulation may enhance the risk of genomic instability and development of 
MDS/AML.12 Smoldering inflammation as a result of aberrant activation of inflammatory pathways (e.g. 
Toll-like receptor (TLR) signaling) can induce malignant transformation and disease progression by 
causing genotoxic cell stress. Indeed, in low risk MDS elevated levels of several stress-inducing 
molecules, such as the damage-associated molecular pattern (DAMP) molecules S100A8/A9, are 
actively secreted from mesenchymal niche cells in the bone marrow (BM) microenvironment, thereby 
causing niche-induced DNA damage in hematopoietic stem and progenitor cells (HSPCs).13 High 
S100A9 levels in MDS BM also result in inflammasome assembly and subsequent initiation of 
pyroptosis, an immunogenic form of cell death, which could potentially explain the high rate of cell 
death in low risk MDS BM.14–16 These soluble inflammatory molecules are able to bind to TLRs on the 
surface of HSPC and immune cells. Constitutively activated TLR-signaling and downstream mitogen-
activated protein kinase (MAPK) and NF-κB activation are evident and have been implicated in the 
pathogenesis of MDS.17–24 Besides active secretion of stress-inducing molecules, passive release 
from cells undergoing immunogenic cell death has also been described in MDS. Levels of high 
mobility group box 1 (HMGB1), a mediator strongly involved in inflammatory processes and a ligand 
for TLR4, were found to be increased in the BM of MDS patients due to impaired clearance of 
apoptotic cells causing secondary necrosis and leakage of this molecule into the BM environment.25  
As a result of this vicious circle of inflammation and cell death, immune-inhibitory mechanisms that 
interfere with this excessive inflammatory process kick in. While these immune-inhibitory pathways 
may control the inflammatory response to some extent, they also facilitate the expansion of 
immunosuppressive cells such as Tregs and MDSCs which further suppress the already weakened 
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immune-surveillance against the malignant clone. Therefore, a delicate balance between immune 
activation and inhibition is required to maintain an effective immunosurveillance. Thrombomodulin 
(TM) is known for its anti-coagulant function by serving as a co-factor for thrombin. Notably, the lectin-
like domain of the TM molecule harbors high anti-inflammatory activities and interferes with the 
complement pathway.26–28 Several studies have shown strong correlations between disease severity 
and TM levels in, for instance, autoimmune and infectious diseases as well as in cancer.29–31 In the 
immune system, TM, also known as CD141 or BDCA-3, is mainly expressed on dendritic cells.32–34 We 
have previously described elevated expression of TM/BDCA-3 on tumor-conditioned and 
immunosuppressive monocyte-derived dendritic cells that acquire a M2-like macrophage 
phenotype.35,36 The anti-inflammatory potential of TM has also been assigned to the fact that TM is 
able to bind HMGB1, thereby inhibiting the high pro-inflammatory function of this molecule. Since high 
levels of this molecule were found in low risk MDS BM, this interactive mechanism may be relevant in 
keeping excessive immune activation to a minimum. The aim of this study was to evaluate the 
possible role and prognostic value of TM in regulating the inflammatory immune response in MDS. 
The expression of TM was evaluated on different monocyte subsets (classical, intermediate and non-
classical) in the peripheral blood (PB) and BM within different MDS risk groups. Multidimensional mass 
cytometry (CyTOF) was used to investigate the putative impact of TM+ monocytes on T cell 
phenotype. Both in the PB as well as in the BM of MDS patients, classical monocytes showed high 
expression of TM on their cell surface compared to healthy donor-derived monocytes. Expression of 
TM was related to a more favorable prognosis and functional skewing of the T cell response to a more 
tolerized state. 
 
Methods 
Patient and control samples 
Twenty-nine peripheral blood (PB) and 154 bone marrow (BM) samples of newly diagnosed MDS 
patients were collected in this study. Patients were assigned to different risk categories using the 
Revised International Prognostic Scoring System (IPSS-R) and the 2016 World Health Organization 
(WHO) classification (details are given in the supplementary methods file and Table 1). A set of 25 
age-matched control BM samples was obtained after written informed consent from hematologically 
healthy patients that were undergoing cardiac surgery at the Amsterdam UMC. For PB analysis 31 
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control samples were collected. The study was approved by the local ethical committee and in 
accordance with the declaration of Helsinki.  
 
Flow cytometry and fluorescence in situ hybridization (FISH)  
PB and BM cells were analyzed on a flow cytometer (FACSCantoTM, BD Biosciences) after incubation 
with a panel of monoclonal antibodies (see supplementary methods for details). Data analysis was 
performed using FlowJo software (Tree star, Ashland, OR, USA). Monocyte subsets were identified 
based on the differential expression of CD14, CD16 and M-DC8 (anti-6-Sulfo LacNAc [Slan]), using 
recent recommendations (Figure S1).37,38 Classical monocytes were characterized by high CD14 
expression, and CD16 and M-DC8 negativity. Intermediate and non-classical monocytes were both 
defined as CD16 positive. However, only intermediate monocytes expressed CD14. We used M-DC8 
as a marker to discriminate between intermediate and non-classical monocytes as suggested by Hofer 
et al (Figure 1A).38  
Three samples containing monocytes with high TM expression and a known cytogenetic aberrancy 
were used for the isolation of classical monocytes and subsequent interphase FISH analysis (details 
are given in supplementary methods). 
 
T cell cultures and multidimensional mass cytometry 
A multi-parameter deep-phenotyping strategy, known as cytometry by time-of-flight (CyTOF), was 
used for T cells cultured in the presence of MDS-derived TM- or TM+ monocytes (culture details can 
be found in the supplementary methods). Data was analyzed using a combination of automated 
dimension reduction and clustering methods including t-distributed stochastic neighbor embedding (t-
SNE)39 to visually (viSNE) identify cell populations.40 This was followed by spanning-tree progression 
analysis of density-normalized events (SPADE)41 for the clustering of T cells as published before.42,43 
The deep immunophenotyping of T cell clusters was performed using our in-house pipeline (publicly 
available here: https://github.com/kordastilab/cytoClustR) followed by Marker Enrichment Modelling 
(MEM) to calculate MEM scores of the identified subpopulations.44 
 
Statistical analysis 
Significant differences for two-group comparisons were analyzed by applying a non-parametric Mann-
Whitney U test, whereas for multi-group comparisons a Kruskal-Wallis with Dunn’s multiple 
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comparisons test was used. A Spearman correlation was computed in peripheral blood and bone 
marrow comparisons. P-values of <0.05 were considered significant. Graphpad Prism 6 software (San 
Diego, USA) was used for graphic display and statistical calculations. A multivariate Cox regression 
analysis for overall and leukemia-free survival was performed by using the IBM SPSS Statistics 
software version 22 (New York, USA).  
 
Results 
Classical monocytes express thrombomodulin in MDS patients 
Monocyte subsets were identified by flow cytometric analysis based on the expression of CD14, CD16 
and M-DC8 according to recently published recommendation.38 Classical, intermediate and non-
classical monocytes were characterized by using the above mentioned markers (Figure 1A). Then, the 
expression of TM and HLA-DR, a major histocompatibility complex (MHC) molecule class II, was 
assessed on all monocyte subsets derived from normal bone marrow (NBM) and MDS BM samples. 
Monocyte subsets from MDS patients showed high levels of TM expression on their cell surface, 
whereas NBM-derived monocytes showed very low levels of TM. Also, HLA-DR expression was higher 
on all monocyte subsets in MDS BM than it was in NBM (Figure 1A). Quantification of these 
expression levels on different monocyte subsets was performed in a larger cohort of patients (n=10 
NBM and n=24 MDS BM samples). Total percentages of monocyte subsets in MDS BM compared to 
NBM were not significantly different. However, the percentage of monocytes that expressed TM was 
significantly higher for MDS-derived classical monocytes compared to the same monocyte subset in 
NBM (37.3% vs 9.9%, p<0.0001, Figure 1B). The percentage of TM expression on intermediate and 
non-classical monocytes was equally distributed between MDS BM and NBM (Figure 1B). The MFI of 
TM and HLA-DR was evaluated on the three distinct monocyte subsets using the same set of 
samples. Similarly, classical monocytes from MDS BM showed higher expression levels of TM 
compared to NBM classical monocytes (3.7-fold, p<0.0001). HLA-DR expression levels were higher 
for all MDS-derived monocyte subsets (classical monocytes: 2.0-fold, p=0.0015; intermediate 
monocytes: 1.8-fold, p=0.0154; non-classical monocytes: 1.5-fold, p<0.0001, Figure 1B). TM 
expression remained unchanged upon overnight stimulation with TLR-ligands in a preliminary set of 
samples (Figure S2). 
Classical monocytes were then analyzed in a larger set of samples since this subset forms the most 
prevalent subset in NBM as well as in MDS BM and it revealed the most prominent difference in TM 
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expression. Also, the peripheral blood (PB) compartment was included in the analysis. The cohort was 
extended with 130 MDS BM-derived samples and 15 NBM samples. The PB and BM samples in the 
extended control and patient cohort (n=31 normal PB (NPB), n=29 MDS PB, n=25 NBM and n=154 
MDS BM) were screened for the presence of TM on classical monocytes (Figure 1C). MDS-derived 
classical monocytes showed elevated expression of TM in both the PB as well as in the BM 
compartment compared to NPB and NBM samples (PB: 33.6% vs 17.8%, p=0.015; BM: 37.0% vs 
8.6%, p<0.0001). Furthermore, a strong positive correlation was found for the percentage of classical 
monocytes expressing TM in the two compartments in 25 paired MDS samples (r=0.83, p<0.0001. 
Figure 1C). In order to study TM expression on other cell types present in the PB and BM 
compartment, the same flow cytometric panel was used. We were able to identify granulocytes, 
eosinophils and B cells. TM was exclusively expressed on MDS-derived monocytes (Figure S3) and 
none of the other cell types in PB and BM showed positivity for TM, including the non-B cell 
lymphocytic compartment consisting of T and NK cells (data not shown). 
 
TM-expressing monocytes are clonally involved and are associated with low risk MDS features  
In order to investigate the clonal involvement of TM positive monocytes in MDS, cells from three 
different patients were sorted and screened for the presence of a known cytogenetic aberration 
according to their karyotype. Almost all monocytes of these patients showed high expression of TM. 
One patient had a deletion of chromosome 5q (del5q) in all cells (karyotype: 
46,XY,del(5)(q22q33)[10]), one showed trisomy for chromosome 8 in 65% of the cells (karyotype: 
47,XY,+8[13]/46,XY[7]) and one case had a monosomy 7 (karyotype: 45,XY,-7[10]). In all cases, TM+ 
monocytes were highly involved in the dysplastic clone and showed a high percentage of cells with the 
respective cytogenetic abnormality, suggesting that they do not come from healthy CD34+ cells. The 
isolated CD34+ progenitor cells showed a similar pattern, since the known cytogenetic aberration was 
present in most analyzed cells. As expected, B cells were not involved. Partial involvement was found 
for whole bone marrow samples (Figure 2A).  
To further correlate TM expression with different MDS subgroups, clinical patient data were collected 
and the IPSS-R, reflecting survival and the risk for disease progression, was calculated. Furthermore, 
patients were categorized by using the 2016 WHO classification system that incorporates clinical 
characteristics, peripheral blood and bone marrow findings and cytogenetic analysis. The percentage 
of monocytes displaying TM expression was higher for patients that had a very low or low risk score in 
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the IPSS-R as compared to patients in higher risk groups and healthy controls (very low/low 40.1% vs 
intermediate 22.7% vs high/very high 28.3% vs NBM 11.3%. Figure 2B). Additionally, TM expression 
was elevated in WHO categories related to lower risk disease such as MDS-SLD and MDS-MLD with 
or without ring sideroblasts (RS) compared to categories related to higher risk MDS, i.e. EB-1 and EB-
2. Compared to NBM, the percentage of monocytes expressing TM was higher in all WHO subgroups 
(SLD/MLD/RS-SLD/RS-MLD 40.9% vs EB-1/EB-2 24.2% vs NBM 11.3%. Figure 2B). Using the 
percentage of BM blast cells as a reflection of disease stage, patients with blast percentages below 
5% harbored higher numbers of TM+ monocytes than patients with 5% or more blast cells (41.3% vs 
25.7%, respectively, p<0.0001. Figure 2C). Finally, a relation between the percentage of monocytes 
expressing TM and the presence of ring sideroblasts (erythroblasts with mitochondrial iron 
accumulation) was found (present 45.4% vs absent 33.2%, p=0.003. Figure 2C). As an “indirect” 
indication of the presence of a SF3B1 mutation, the percentage of TM+ monocytes was compared 
between RS subtypes and other MDS subtypes (Figure S4). Significant higher percentages of TM+ 
monocytes in RS cases was found compared to EB-I/II. A trend of higher frequencies was observed 
for the comparisons with other subtypes. 
 
MDS-derived TM+ monocytes polarize CD4+ T cells to an immunosuppressive phenotype 
The next research question was to study the effect of TM+ monocytes on the phenotype of CD4+ T 
cells and whether they could induce an anti-inflammatory T cell phenotype. Healthy donor-derived 
CD4+ T cells were co-cultured with sorted TM- or TM+ monocytes from two MDS patients (Figure S5). 
After 5 days, T cells were harvested and labelled with a comprehensive panel of metal tagged 
antibodies (Table S1) for mass cytometry (CyTOF). Using our data analysis pipeline, T cell subsets 
were identified (Figure S6) and compared between the conditions (i.e. day zero, control stimulated and 
cultures with TM- or TM+ monocytes. Figure 3A). Compared to day zero, all conditions showed 
expansion of specific T cell subsets. To further characterize these cell islands, T cells were clustered 
by SPADE on tSNE (see materials and methods). Using selected T cell markers various subsets could 
be characterized (Figure 3B). Then frequencies of clusters between the conditions were compared 
(Figure 3C). Nodes highlighted with red circles refer to the most frequent T cell clusters in the TM- 
condition whereas black circles indicate a higher percentage in the TM+ condition. For both conditions 
the top 5 of highest frequencies was selected. The expression profiles of T cells in the identified 
clusters were evaluated next, using MEM (see materials and methods). T cell clusters were divided 
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into two groups for comparison: clusters with highest frequency in the TM+ condition (called “up”) and 
clusters with highest frequency in the TM- condition (called “down”). MEM scores were calculated for 
each marker in each group for further comparison.44 Interestingly, T cells that are predominantly 
present upon culturing with TM+ monocytes (group called “up”) show an anti-inflammatory profile 
(Figure 3C). They are polarized toward Th2, Treg and PD-1 expressing clusters of T cells, since they 
express high levels of FoxP3, GATA3 and CD279 (PD-1) and have elevated concentrations of 
intracellularly measured IL-4 and IL-10. In contrast, T cells cultured in the presence of TM- monocytes 
(group called “down”) are mainly positive for IFN-y and hardly for immunosuppressive cytokines.  
 
The presence of TM+ monocytes is related to a better overall and leukemia-free survival  
In order to determine the clinical significance of the presence of TM+ monocytes the overall survival 
(OS) and leukemia-free survival (LFS) were calculated. As a cut-off for TM expression monocytes from 
the healthy donor cohort were used. The mean TM percentage plus 2SD was calculated resulting in a 
cut-off of 25.53%. In total, OS data for 122 MDS patients and LFS data for 102 patients was available. 
Interestingly, the presence of TM on MDS monocytes was significantly associated with a better OS 
(p=0.006) as well as a better LFS (p=0.029. Figure 4A). The median OS for patients with TM+ 
monocytes was 58 months, whereas the median OS without TM+ monocytes was 30 months. For a 
subgroup of patients, data were available for further risk stratification into IPSS and IPSS-R risk 
groups. Following the hypothesis that TM is mainly present in an inflammatory environment, survival 
and LFS data was also analyzed in low risk MDS groups (i.e. IPSS low and intermediate groups or 
IPSS-R very low, low and intermediate groups). Similarly, the presence of TM+ monocytes in this 
subgroup of patients resulted in a better overall survival (Figure 4B). Probably because of low patient 
numbers a difference in LFS didn’t reach significance (Figure 4C). To test if TM as a single marker has 
an independent prognostic value in overall and leukemia-free survival a multivariate Cox regression 
analysis with backward stepwise elimination was performed. Covariates that were included in this 
analysis included hemoglobin levels, absolute neutrophil count, platelet count, bone marrow blast 
percentage, cytogenetic risk group and percentage of TM expression on monocytes. For 60 patients 
information on all variables was available (not shown). Covariates with a p-value of >0.10 were 
removed. Both the cytogenetic risk group as well as the percentage of TM expression were predictive 
markers for OS (p=0.001 and p=0.064 respectively). For LFS the percentage of blast and TM 
expression had predictive value (p=0.010 and p=0.077 respectively). 
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Discussion 
The BM microenvironment in MDS, and particularly in low risk groups, is often characterized by the 
presence of pro-inflammatory cells and molecules. While an increased inflammation and subsequent 
cellular immune response is crucial to eliminate malignant cells, the continuous immune stimulation 
could lead to genomic instability and inevitable malignant transformation.12 Identifying the factors that 
could maintain a healthy overall immune response in MDS is important and clinically relevant.  In mice, 
it has been shown that lack of the lectin-like domain of TM leads to reduced survival after endotoxin 
exposure, whereas a recombinant form diminished NF-κB and MAPK activation.45 In the current study, 
we therefore investigated the presence of TM on immune cells in MDS-derived BM and PB samples 
and its immune-modulatory role in MDS. TM was mainly expressed on monocyte subsets and not on 
granulocytes, lymphocytes or eosinophils. The difference in TM expression between monocytes of 
healthy donors and MDS was most evident for classical monocytes. FISH analysis showed clonal 
involvement for these TM+ monocytes. This subset showed hardly any TM expression on either 
healthy BM- or healthy PB-derived cells. In MDS patients there was a high variation in monocytes 
expressing TM. Some patients showed expression levels similar to healthy donor-derived monocytes, 
whereas for others nearly all monocytes expressed TM. We found that the percentage of TM 
expression was evidently higher in low risk groups as compared to higher risk categories, suggesting 
that the presence of TM may be primarily observed in a pro-inflammatory environment (i.e. low risk 
MDS). Interestingly, Talati et al previously described a correlation between the presence of classical 
monocytosis in MDS and favorable prognostic factors such as increased white blood cell counts and 
absolute neutrophil counts.46 Furthermore, an increased percentage of monocytes was associated 
with lower MDS risk groups and good-risk cytogenetics. SF3B1 was present in greater frequency in 
this MDS group and overall survival tended to be better for these patients. In this perspective, it would 
be interesting to investigate the presence of TM in a same set of samples in future research.   
Besides active secretion and passive release of inflammatory molecules in the MDS BM environment, 
certain T cell subsets, particularly Th1 and Th17 type T cells, contribute to an immune-active state by 
the secretion of high amounts of interferon (IFN)-γ and IL-17. In order to investigate the effect of 
monocytes on T cell skewing, healthy T cells were cultured in the presence of TM+ or TM- MDS 
monocytes. Using mass cytometry, we were able to utilize a comprehensive panel of surface and 
intracellular markers for this purpose. Interestingly, T cells cultured in the presence of TM+ monocytes 
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showed an anti-inflammatory skewed profile. They showed less IFN-γ positivity and higher 
concentrations of IL-4 and IL-10 were measured intracellularly compared to T cells cultured with TM- 
monocytes. While the number of patients’ samples are limited and data need to be interpreted with 
caution, these data suggest that TM+ monocytes polarize T cells toward Th2 and/or Treg phenotypes.  
Altogether, our data point to an interesting function for TM-expressing monocytes in the highly 
inflammatory environment of low risk MDS patients. They could play an essential role in dampening 
disproportionate immune activation by inducing anti-inflammatory T cell subsets. In keeping with this 
notion, overall and leukemia-free survival was better for patients in which the BM contained TM+ 
monocytes than for patients lacking TM expression, supporting a clinically relevant mechanism. 
Nevertheless, in longer term, this mechanism could lead to a profound immunosuppressive state 
which prevent effective immune surveillance; a common condition in higher risk MDS. 
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Table 1. Patient and control characteristics 
Characteristics   Value             [min-max] 
Total # 
  
HD 56  
MDS 183  
Peripheral blood samples 
  
Number 60  
HD 31  
MDS 29  
Age – mean, y   
HD -  
MDS 69 [45-85] 
Sex   
HD – male/female -  
MDS – male/female 20/9  
Bone marrow samples 
  
Number 179  
HD 25  
MDS 154  
Age – mean,y   
HD 62 [20-86] 
MDS 69 [36-94] 
Sex   
HD – male/female 18/7  
MDS – male/female 110/44  
IPSS-R   
Very low risk 20  
Low risk 34  
Intermediate risk 22  
High risk 8  
Very high risk 8  
WHO   
MDS-SLD 5  
MDS-MLD 48  
MDS-RS-SLD 8  
MDS-RS-MLD 27  
MDS-EB1 22  
MDS-EB2 20  
Del5q 12  
% Blasts   
<5% 97  
≥5% 44  
Ring sideroblasts   
No 106  
Yes 40  
Abbreviations: EB, excess blasts; HD, healthy donor; MLD, 
multilineage dysplasia; RS, ring sideroblasts; SLD, single lineage 
dysplasia; WHO, World Health Organisation; y, years.   
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Figure legends 
Figure 1. TM-expressing monocyte subsets in normal and MDS bone marrow and peripheral 
blood samples. (A) Identification of different monocyte subsets in normal bone marrow (NBM) and 
MDS BM. Three markers, CD14, CD16 and M-DC8, were used to identify classical (CD14++CD16-M-
DC8-, in orange), intermediate (CD14+CD16+M-DC8-, in purple) and non-classical monocytes 
(CD14+/-CD16+M-DC8+, in green). The expression levels of thrombomodulin (TM) and HLA-DR were 
assessed on all separate monocyte subsets. The median fluorescence intensity (MFI) value for each 
subset is shown for a representative sample. (B) Frequencies of monocyte subsets in the BM of 10 
healthy individuals and 24 MDS patients. Percentages were calculated from the total CD45+ 
mononuclear cell fraction. Mean frequencies ± SEM are given (NBM vs MDS BM: classical monocytes 
11.47% SEM ± 1.86 vs 11.11% SEM ± 2.20, intermediate monocytes 0.45% SEM ± 0.12 vs 0.85% 
SEM ± 0.17, non-classical monocytes 0.46% SEM ± 0.11 vs 0.38% SEM ± 0.05). Furthermore, the 
percentage of monocytes that express TM is displayed (NBM vs MDS BM: classical monocytes 9.94% 
SEM ± 2.82 vs 37.27% SEM ± 4.00, intermediate monocytes 42.60% SEM ± 7.27 vs 54.90% SEM ± 
3.48, non-classical monocytes 45.11% SEM ± 3.72 vs 49.46% SEM ± 3.34). Expression levels of 
thrombomodulin and HLA-DR on NBM and MDS BM monocyte subsets are also displayed. Mean MFI 
values ± SEM are shown for 10 NBM and 24 MDS BM samples (TM in NBM vs MDS BM: classical 
monocytes 382 SEM ± 65 vs 1425 SEM ± 367, intermediate monocytes 1414 SEM ± 245 vs 2208 
SEM ± 259, non-classical monocytes 1279 SEM ± 169 vs 1676 SEM ± 144. HLA-DR in NBM vs MDS 
BM: classical monocytes 5426 SEM ± 715 vs 11010 SEM ± 1056, intermediate monocytes 20062 
SEM ± 2529 vs 35639 SEM ± 3989, non-classical monocytes 10117 SEM ± 856 vs 15255 SEM ± 
1915). (C) Percentage of TM-expressing classical monocytes in peripheral blood (PB) and bone 
marrow (BM). Bars indicate mean frequencies (Normal PB (NPB; n=31) vs MDS PB (n=29): 17.8% vs 
33.6%. Normal BM (NBM; n=25) vs MDS BM (n=154): 8.6% vs 37.0%). Thrombomodulin expression 
was correlated in peripheral blood- and bone marrow-derived classical monocytes. In total, 25 paired 
MDS samples were included. * p<0.05, ** p<0.01, **** p<0.0001. 
 
Figure 2. Classical monocytes are clonally involved and the presence of thrombomodulin 
correlates with disease states. (A) Sorted cells, including B cells and CD34+ blast cells, from 
patients with a known cytogenetic aberrancy were subjected to a FISH analysis. Furthermore, whole 
BM samples were used for degree of cytogenetic load. Representative interphase cells hybridized with 
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the chromosome 5q probe, showing loss of 5q in CD34+ blasts and monocytes, and no loss of 5q in 
B-cells are shown. In three tested cases (monosomy 7, del 5q and trisomy 8), classical monocytes and 
CD34+ blast cells were highly involved in the dysplastic clone, whereas B cells were not involved. 
Interphase FISH on whole bone marrow samples showed both an aberrant and a normal cell line. (B) 
TM+ classical monocytes in different risk groups within the IPSS-R and according to the WHO2016 
classification. The highest percentage of classical monocytes that express TM is found in the very low-
low risk groups, whereas in higher risk groups the percentage of TM expression is significantly 
reduced compared to low risk disease (NBM (n=25) 11.3% SEM ± 3.0% vs very low/low (n=54) 40.1% 
SEM ± 2.9% vs intermediate (n=22) 22.7% SEM ± 3.7% vs high/very high (n=16) 28.3% SEM ± 4.9%). 
Patients having a low risk-related WHO2016 classification (SLD/MLD/RS-SLD/RS-MLD) show higher 
percentages of TM expression on monocytes compared to higher risk groups (EB-1/EB-2) and NBM. 
(NBM (n=25) 11.3% SEM ± 3.0% vs SLD/MLD/RS-SLD/RS-MLD (n=87) 40.9% SEM ± 2.3% vs EB-
1/EB-2 (n=42) 24.2% SEM ± 2.7%). (C) The percentage of classical monocytes that is positive for TM 
in patients with low and higher blast counts. In the group of patients that have blast counts below 5%, 
the percentage of monocytes expressing TM is significantly higher compared to the group of patients 
with blast counts ≥5% (<5% (n=97) 41.3% SEM ± 2.2% vs ≥5% (n=44) 25.7% SEM ± 2.8%). Patients 
with ring sideroblasts show higher percentages of monocytes positive for TM than patients that do not 
have ring sideroblasts present (Yes (n=40) 45.4% SEM ± 3.7% vs No (n=106) 33.2% SEM ± 2.0%). * 
p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. Abbreviations: EB, excess blasts; IPSS-R, Revised 
International Prognostic Scoring System; MLD, multilineage dysplasia; NBM, normal bone marrow; 
RS-MLD, ringed sideroblasts with multilineage dysplasia; RS-SLD, ringed sideroblasts with single 
lineage dysplasia; SLD, single lineage dysplasia.  
 
Figure 3. Deep phenotyping of T cells after co-culture with TM- or TM+ MDS monocytes. Healthy 
donor-derived CD4+ T cells were co-cultured with MDS TM- or TM+ monocytes (from 2 MDS 
patients), or in the stimulated control condition with plate-bounded anti-CD3 antibody only. After a 5-
days culture, T cells were stained with an extensive panel of surface and intracellular markers as well 
as transcription factors and cytokines and analyzed using mass cytometry (CyTOF). (A) Viable T cells 
were identified and visualized using viSNE. Different T cells subsets were identified based on IFN-γ, 
GATA3, IL-17, IL-4, FoxP3 and CD127 (Th1 were considered to be IFN-y+, IL-17 and GATA3-; Th2 
were GATA3+IL-4+; Th17 were IL-17+; Tregs were CD127- and FoxP3+CD25+ and IFN-γ-. Figure 
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S6). Overlays were created from condition-specific biaxial viSNE contour plots and each individual T 
cell subset. T cell populations at start of the experiment (D=0) and after 5 days of culture with anti-CD3 
only, TM- monocytes or TM+ monocytes are shown for a representative sample. (B) Cells were then 
further clustered with SPADE into 50 nodes using the clustering channels tSNE1 and tSNE2. Different 
clusters of nodes representing various T cell subsets could be identified in the stimulated control 
condition by using selected markers. The color intensity in each node reflects the expression level of 
the indicated marker and the size of the node reveals the number of cells involved. (C) Frequencies of 
all clusters were compared between the TM- and TM+ conditions. T cell clusters that were most 
prevalent in the TM- condition are highlighted in red. Black circles represent clusters that show higher 
percentages in the TM+ condition. The top 5 of highest frequencies for both conditions is shown. 
Using MEM, profiles of T cell clusters with highest frequencies in TM- or TM+ cells were characterized. 
Two subgroups of clusters were generated: 1) five nodes with highest frequency in TM+ condition 
(called “up”), 2) five nodes with highest frequency in TM- condition (called “down”). Expression levels 
of given markers are shown for the TM+ as well as the TM- conditions, showing that global expression 
in the identified set of clusters for the different markers is nearly similar in both conditions. MEM 
scores were calculated for the markers and results are presented in a heat map. The group of nodes 
that are present in a higher percentage in cultures with TM+ monocytes compared to cultures with TM- 
monocytes reflect an anti-inflammatory profile. T cells in this group (all within “non-Treg nodes”) 
express higher levels of FoxP3, GATA3, CD279 (PD-1), IL-4 and IL-10, a phenotype which suggests 
they are polarizing toward Treg phenotype. Abbreviations: Ir, iridium; MEM, Marker Enrichment 
Modelling; Rh, rhodium; SPADE, spanning-tree progression analysis of density-normalized events; 
TM, thrombomodulin; tSNE, t-Distributed Stochastic Neighbor Embedding.  
 
Figure 4. Overall and leukemia-free survival is related to the presence of TM+ monocytes. As a 
cut-off percentage for the presence of TM on MDS monocytes, expression rates in the healthy donor 
cohort was used. The mean percentage + 2SD was calculated resulting in a cut-off of 25.53%. 
Statistical differences were calculated using the log-rank test. (A) Overall survival data for 122 MDS 
patients and leukemia-free survival data for 102 patients. A significant difference in overall survival 
was found between the presence and absence of TM on monocytes in MDS BM (p= 0.006). The 
median overall survival for patients with TM+ monocytes was 58 months and for patients without TM 
30 months. The time to development of leukemia was significantly longer for patients with TM 
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expression compared to patients without TM expression (p= 0.029). (B) Patients were further selected 
based on their low risk status. Survival curves are shown for the presence and absence of TM+ 
monocytes in low risk patients according to the IPSS and IPSS-R. (C) Additionally, the leukemia-free 
survival for low risk patients is shown in the TM+ and TM- group. Abbreviations: IPSS, International 
Prognostic Scoring System; IPSS-R, Revised International Prognostic Scoring System; LFS, 
leukemia-free survival; TM, thrombomodulin. 
 




 1 
Supplementary methods 1 
Patient and control samples 2 
IPSS-R risk groups of 92 patients could be calculated.  In total, 20 patients were considered very low 3 
risk, 34 low risk, 22 intermediate, 8 high and 8 very high risk. The 2016 World Health Organization 4 
(WHO) classification was available for 142 patients. Five patients could be classified as MDS with 5 
single lineage dysplasia (MDS-SLD), 48 as MDS with multilineage dysplasia (MDS-MLD), 8 as MDS 6 
with ringed sideroblasts with single lineage dysplasia (MDS-RS-SLD), 27 as MDS with ringed 7 
sideroblasts with multilineage dysplasia (MDS-RS-MLD), 22 as MDS with excess blasts-1 (MDS-EB-8 
1) and 20 patients had MDS with excess blasts-2 (MDS-EB-2). Furthermore, 12 patients were 9 
assigned to the group involving isolated deletion of chromosome 5q (Table 1). 10 
Flow cytometric analysis was performed on total white blood cells after erythrocyte lysis. 11 
Furthermore, BM samples were centrifuged on high speed programs for the collection of platelet-12 
poor BM-derived plasma. These samples were stored at -30C until they were used for cytokine 13 
analyses. 14 
 15 
Flow cytometry 16 
PB and BM cells were analyzed on a flow cytometer (FACSCantoTM, BD Biosciences) after 17 
incubation with a panel of monoclonal antibodies (mAb) consisting of M-DC8-FITC and CD303-FITC 18 
(both Miltenyi Biotec, Utrecht, The Netherlands), CD16-PE (Beckman Coulter, Brea, USA), CD11c-19 
PerCP-Cy5.5 (BD Biosciences), CD1c-Pe-Cy7 (eBioscience, San Diego, USA), CD141-APC 20 
(Miltenyi Biotec), CD14/CD19-APC-H7, HLA-DR-V450 and CD45-KO (all, BD Biosciences).  21 
Frequencies of classical, intermediate and non-classical monocytes were calculated as percentage 22 
of CD45+ mononuclear cells (MNC). Median fluorescence intensity (MFI) levels of TM 23 
(CD141/BDCA-3) and HLA-DR were measured on all three subsets and percentages of monocytes 24 
positive for TM were calculated as percentage of total monocytes as well as of CD45+ MNC. 25 
Furthermore, TM expression on MDS-derived monocytes was evaluated after overnight stimulation 26 
and compared to TM expression at baseline (Figure S2). For further functional assays, only 27 
stimulated monocytes were used and no unstimulated condition was included (also because of 28 
limited cell numbers). Without stimulation co-stimulatory molecules, mainly CD80, were not up-29 
regulated as compared to stimulated conditions (Figure S2).  30 
 2 
 1 
Fluorescence in situ hybridization (FISH)  2 
Frozen vials with MNC were rapidly thawed and stained with a monoclonal antibody cocktail 3 
containing M-DC8, CD1c, CD11c, CD14, CD19, CD34, CD45, CD141 and HLA-DR. TM+ monocytes, 4 
CD34+ myeloid progenitor cells and CD19+ B cells were flow cytometrically sorted (BD FACSAriaTM). 5 
Cells were collected in small Eppendorf tubes and further processed for interphase FISH analysis. 6 
They were fixed with 3:1 methanol/acetic acid and transferred to a microscopic slide. FISH was 7 
performed on each sorted cell sample according to the manufacturer’s protocol using probes LSI 8 
EGR1(5q31)/D5S23,D5S721(5p15.2) Dual Colour Probe Set, LSI D7S486(7q31)/CEP7, and  LSI 9 
CEP8 (D8Z2) (all probes from Abbott  Molecular, Des Plaines, IL). For each probe at least 100 cells 10 
were investigated. In samples with less than 100 cells on the slide, all cells present were evaluated.   11 
 12 
T cell cultures and multidimensional mass cytometry 13 
TM- and TM+ monocytes from fresh samples of two MDS patients (MDS-RS-MLD) were flow 14 
cytometrically sorted (Figure S4). They were incubated and stimulated overnight with the TLR-4 15 
ligand LPS (100 ng/ml, Sigma-Aldrich, St. Louis, USA). Next, total CD4+ T cells were derived from 16 
a healthy donor by magnetic isolation (Miltenyi Biotec, Utrecht, The Netherlands). Thereafter, T cells 17 
were co-cultured with either TM- or TM+ MDS monocytes on a plate pre-coated with anti-CD3 in a 18 
ratio of 1:10 for 5 days. T cells from day zero, cultured in the presence of monocytes, or cultured 19 
alone were stained with an extensive antibody panel containing cell surface markers, transcription 20 
factors and cytokines. Each antibody was tagged to a metal isotope (Table S1) and data was 21 
acquired on a Helios mass cytometer (Fluidigm).  22 
 23 
Figure S1. Gating strategy for different monocyte subsets. First, doublets were removed and the CD45+ mononuclear cell (MNC) fraction was selected. 
Monocytes were gated based on CD16/CD14 and CD45/SSC characteristics. Lymphocytes were removed. Then classical monocytes were identified 
using CD11c, HLA-DR and high expression of CD14. Intermediate monocytes were gated by using CD16, negative to intermediate expression of CD14 
and negativity for M-DC8. The population was cleaned up by a HLA-DR/CD11c gate. CD16/M-DC8 was used for the identification of non-classical 
monocytes directly from the CD45+ MNC. 
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Table S1. Antibody panel for mass cytometry staining 
protocol with cell surface markers, cytokines and transcription factors.
